Megan M. O’Meara

Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study

Anas Younes, Joseph M. Connors, Steven I. Park et al. · The Lancet Oncology · 2013 · 269 citations

Dose-escalation Study, Lymphoid Neoplasia, Medicine +8

A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia

Eytan M. Stein, Roland B. Walter, Harry P. Erba et al. · Blood · 2017 · 177 citations · Full text

A phase 1 trial of vadastuximab talirine combined with hypomethylating agents in patients with CD33-positive AML

Amir T. Fathi, Harry P. Erba, Jeffrey E. Lancet et al. · Blood · 2018 · 102 citations · Full text

Aberrant Methylation of the Maspin Promoter Is an Early Event in Human Breast Cancer

Bernard W. Futscher, Megan M. O’Meara, Christina J. Kim et al. · Neoplasia · 2004 · 72 citations · Full text

Disruption of GPR35 Exacerbates Dextran Sulfate Sodium-Induced Colitis in Mice

Shukkur M. Farooq, Yuning Hou, Hainan Li et al. · Digestive Diseases and Sciences · 2018 · 72 citations

Inflammation, Mucosal Immunology, Medicine +6